Dianne Bosch

Ms. Dianne Bosch

Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
orcid
Urology Resident / PhD Candidate

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Dianne BoschDianne Bosch
Dianne Bosch
MKMalou C. P. Kuppen
Malou C. P. Kuppen
MTMetin Tascilar
Metin Tascilar
Tineke J. SmildeTineke J. Smilde
Tineke J. Smilde
PMPeter F.A. Mulders
Peter F.A. Mulders
IOInge M. van Oort
Inge M. van Oort
Background: Manual data collection is still the gold standard for disease-specific patient registries. However, CAPRI-3 uses text mining (an artificial intelligence (AI) technology) for patient identification and data collection. The aim of this study is to demonstrate the reliability and efficiency of this AI-driven approach. Methods: CAPRI-3 is an observational retrospective multicenter cohort registry on metastatic prostate cancer. We tested the patient-identification algorithm and automated data extraction through manual validation of the same patients in two pilots in 2019 and 2022. Results: Pilot one identified 2030 patients and pilot two 9464 patients. The negative predictive value of the algorithm was maximized to prevent false exclusions and reached 94.8%. The completeness and accuracy of the automated data extraction were 92.3% or higher, except for date fields and inaccessible data (images/pdf) (10–88.9%). Additional manual quality control took over 3 h less time per patient than the original fully manual CAPRI registry (105 vs. 300 min). Conclusions: The CAPRI-3 patient-identification algorithm is a sound replacement for excluding ineligible candidates. The AI-driven data extraction is largely accurate and complete, but manual quality control is needed for less reliable and inaccessible data. Overall, the AI-driven approach of the CAPRI-3 registry is reliable and timesaving.

29 February 2024 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
Dianne BoschDianne Bosch
Dianne Bosch
KVKim J.M. van der Velden
Kim J.M. van der Velden
IOIrma M. Oving
Irma M. Oving
DWDirk N.J. Wyndaele
Dirk N.J. Wyndaele
LWLeo E. Weijs
Leo E. Weijs
IOInge M. van Oort
Inge M. van Oort
Imaging before 223Ra-dichloride (223Ra) therapy is crucial for selecting metastatic castration-resistant prostate cancer (mCRPC) patients with bone-only disease. The purpose of this study was to evaluate if baseline prostate-specific membrane antigen (PSMA) PET/CT (bPSMA) versus CT is associated with outcomes of 223Ra therapy. Methods: A secondary analysis of the data of a prospective observational study (NCT04995614) was performed. Patients received a maximum of 6 223Ra cycles and were retrospectively divided into the bPSMA or baseline CT (bCT) groups. All patients received baseline bone scintigraphy. Primary endpoints were alkaline phosphatase and prostate-specific antigen response. Secondary endpoints were overall survival (OS) and radiologic response. Results: Between 2017 and 2020, 122 mCRPC patients were included: 18 (14.8%) in the bPSMA group and 104 (85.2%) in the bCT group. All baseline characteristics were comparable. No significant differences in alkaline phosphatase or prostate-specific antigen response were found. The bCT group showed an OS significantly shorter than that of the bPSMA group (12.4 vs. 19.9 mo, P = 0.038). In 31 of 76 patients (40.1%) in the bCT group who also received posttherapy CT, lymph node or visceral metastases (soft-tissue involvement [STI]) were detected after 223Ra therapy, compared with 0 of 15 patients in the bPSMA group who received posttherapy PSMA PET/CT or CT. No significant difference in OS was found between patients in the bCT or posttherapy CT subgroup without STI (46/76) and the bPSMA group. Conclusion: bPSMA versus CT does not seem to impact biochemical response during 223Ra therapy in mCRPC patients. Nevertheless, patients in the bCT group had a significantly shorter OS, most likely due to underdetection of STI in this group. Therefore, replacing bCT with PSMA PET/CT appears to be a valuable screening method for identifying patients who will benefit most from 223Ra therapy. Visual Abstract

27 October 2020 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
Dianne BoschDianne Bosch
Dianne Bosch
LLLaura W. Leicher
Laura W. Leicher
NVNina C.A. Vermeer
Nina C.A. Vermeer
KPKoen C.M.J. Peeters
Koen C.M.J. Peeters
WCWouter H de Vos tot Nederveen Cappel
Wouter H de Vos tot Nederveen Cappel
HWHenderik L. van Westreenen
Henderik L. van Westreenen

9 May 2026 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
Dianne BoschDianne Bosch
Dianne Bosch
KVKim J. M. van der Velden
Kim J. M. van der Velden
ABAart Beeker
Aart Beeker
HBHendrik P. van Den Berg
Hendrik P. van Den Berg
ABAndré M. Bergman
André M. Bergman
IOInge M. van Oort
Inge M. van Oort
In November 2020, olaparib became the first approved poly adenosine diphosphate (ADP)-ribose polymerase inhibitor (PARPi) for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations (BRCAm) in the Netherlands. As randomized clinical trials include fitter patients, their findings may not fully reflect real-world outcomes. The aim was to evaluate genomic testing practice and subsequent use and outcomes of olaparib monotherapy in a real-world BRCAm mCRPC population. Data were derived from ten hospitals in the Dutch CAPRI-3 registry, including mCRPC patients diagnosed between 2016 and 2021. Those receiving olaparib in standard-of-care treatment after its national approval (from November 2020) were analyzed and grouped as taxane-naïve (TN) or post-taxane (PT). The primary endpoint was overall survival (OS). Among 1996 mCRPC patients, genomic analysis (somatic and/or germline) was performed in 23.4% (range 3.8-63.2% across hospitals), identifying BRCAm in 11.3% of patients. Tested patients differed significantly in age, comorbidities, and prior treatment. Among 35 eligible BRCAm patients, 27 (77.1%) received olaparib. TN patients (8/27) were significantly older and initiated olaparib at an earlier line of therapy. Median OS was 28.7 months (95% confidence interval (CI) not reached) in TN versus 10.5 months (95% CI 9.6-11.5) in PT patients (p = 0.003). Limitations include the retrospective design and small subgroups. Genomic testing application remained limited and uneven across centers. Most eligible patients received olaparib; TN patients seemed to benefit most.

16 June 2025 in Oncology and Therapy
Verified
Journal Article
Open access
PDF file
RWRachel Weinrib
Rachel Weinrib
JFJoan Fortuny
Joan Fortuny
DMDavid Martinez
David Martinez
BKBianca Kollhorst
Bianca Kollhorst
UHUlrike Haug
Ulrike Haug
ZVZdravko Vassilev
Zdravko Vassilev
Introduction Radium-223 is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, without visceral metastases, who progress after at least (≥) two lines of or are ineligible for other systemic therapies (besides luteinising hormone–releasing hormone analogues). Radium-223 is contraindicated in combination with abiraterone acetate and prednisone/prednisolone. Point 2 and the contraindication above were added to the 2018 European Medicines Agency (EMA) label. In the observational cohort study reported here, we evaluated compliance with the 2018 revised label. Methods The proportion of patients with mCRPC who initiated radium-223 in the Netherlands, Germany and Denmark was analysed descriptively before (2013–2017) and after (2019–2020) the label change, allowing ≥ 6 months of follow-up. No a priori hypotheses were evaluated. Results A total of 1070 patients were included in this observational cohort study (before/after the label change: Netherlands [243/53]; Germany [580/71]; Denmark [60/63]). Radium-223 use with abiraterone acetate or other systemic mCRPC therapies was limited and decreased after the label change in the Netherlands and Germany; in Denmark, combined use was not observed before the label change and was observed only rarely after the label change. After the label change, radium-223 use without ≥ 2 prior lines of systemic mCRPC therapy decreased in all countries, despite remaining relatively common in the Netherlands and Germany. Conclusions Radium-223 use in combination with abiraterone acetate or other systemic mCRPC therapies largely aligned with the 2018 EMA label change. However, after the label change, radium-223 use without ≥ 2 prior lines of systemic mCRPC therapy remained relatively common in the Netherlands and Germany, possibly because radium-223 was previously recommended as first-line treatment for frail patients, and doctors still may consider it for use in these cases. We could not assess patients’ eligibility for other systemic mCRPC therapies; therefore, these findings may partly reflect radium-223 on-label use in patients with contraindications for other systemic therapies. EMA Study Identification Number EUPAS37163.

20 October 2023 in Annals of Oncology
Verified
Journal Article
Closed access
Dianne BoschDianne Bosch
Dianne Bosch
KVK. van der Velden
K. van der Velden
IOI.M. Oving
I.M. Oving
DWD.N.J. Wyndaele
D.N.J. Wyndaele
LWL.E. Weijs
L.E. Weijs
IOI.M. van Oort
I.M. van Oort